Esmilkrys Ramirez, MD
Obesity Medicine · Chicago, ILNPI 1083880546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 653 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.
Across 653 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- AbbVie$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Bioventus LLC$1K
- plus $4K from 29 others
What the payments were for
- Travel & lodging$8916%
- Food & beverage$13,83993%
- Education$1411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 124 | $3,110 |
| Novo Nordisk | 120 | $1,966 |
| AbbVie(2 entities) | 86 | $1,761 |
| Lilly USA, LLC | 72 | $1,431 |
| Boehringer Ingelheim | 50 | $1,167 |
| Bioventus LLC | 5 | $1,005 |
| Bayer | 29 | $890 |
| Amgen | 28 | $604 |
| Pfizer | 24 | $498 |
| Corcept Therapeutics | 6 | $373 |
| Merck | 20 | $317 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $306 |
| GSK | 8 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $167 |
| Sanofi-aventis U.S. LLC | 6 | $135 |
| Johnson & Johnson | 5 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $121 |
| Ardelyx, Inc. | 4 | $108 |
| Exact Sciences | 4 | $106 |
| Seqirus USA Inc | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| VBI Vaccine (delaware) Inc. | 3 | $60 |
| Redhill Biopharma Inc. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Gilead | 1 | $19 |
| Eli Lilly | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $112,357 |
| JardianceEmpagliflozin | 73 | $105,129 |
| FarxigaDapagliflozin Propanediol | 69 | $86,315 |
| ProliaDenosumab | 44 | $75,684 |
| TrulicityDulaglutide | 63 | $66,281 |
| TradjentaLinagliptin | 54 | $53,907 |
| LinzessLinaclotide | 22 | $28,756 |
| MounjaroTirzepatide | 19 | $22,734 |
| JanuviaSitagliptin Phosphate | 16 | $20,812 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 88 | $19,780 |
| EliquisApixaban | 12 | $17,930 |
| EntrestoSacubitril/Valsartan | 16 | $14,152 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 21 | $6,648 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 71 | $5,004 |
| Novolog FlexpenInsulin Aspart | 15 | $3,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $1,167 | $159,036127 claims |
| Novo NordiskOzempic | $1,966 | $112,357114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,431 | $89,01582 claims |
| AstraZenecaFarxiga | $3,110 | $86,31569 claims |
| AmgenProlia | $604 | $75,68444 claims |
| AbbVieLinzess, Synthroid | $1,761 | $29,68134 claims |
| GSKShingrix, Arexvy | $168 | $26,428109 claims |
| MerckJanuvia | $317 | $20,81216 claims |
| PfizerEliquis | $498 | $17,93012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Chicago
- Mona LalaChicago$822
- Omar ShamsiElmhurst$39K
- Jeffrey PuaWestmont$25K
- Diana PlataArlington Heights$19K
- Diala AlatassiElmhurst$815
- Esther SchulzMount Vernon$485
- Catherine JohnsonClarendon Hills$324
- Darshan PatelDeer Park$266
- Lyndsay HoffmanArlington Heights$219
- Manali PatelBloomingdale$211
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.